Market Closed -
Hong Kong S.E.
04:08:03 2024-03-28 am EDT
|
5-day change
|
1st Jan Change
|
3.66
HKD
|
-3.94%
|
|
-.--%
|
-50.47%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Capitalization
1 |
15,022
|
7,261
|
5,677
|
2,282
|
2,282
|
-
|
Enterprise Value (EV)
1 |
12,573
|
4,972
|
4,140
|
4,536
|
1,802
|
2,098
|
P/E ratio
|
-
|
-12.6
x
|
-13.8
x
|
-11.6
x
|
-9.39
x
|
-28.2
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
389
x
|
53.2
x
|
22.6
x
|
10.3
x
|
3.35
x
|
2.43
x
|
EV / Revenue
|
325
x
|
36.4
x
|
16.5
x
|
10.3
x
|
2.64
x
|
2.24
x
|
EV / EBITDA
|
-32.7
x
|
-23
x
|
-8
x
|
-12.1
x
|
-10.1
x
|
-35.5
x
|
EV / FCF
|
-60.9
x
|
-9.82
x
|
-7.16
x
|
-2.73
x
|
-3.88
x
|
-7.44
x
|
FCF Yield
|
-1.64%
|
-10.2%
|
-14%
|
-36.7%
|
-25.8%
|
-13.4%
|
Price to Book
|
5.33
x
|
2.39
x
|
2.15
x
|
0.98
x
|
1.15
x
|
1.19
x
|
Nbr of stocks (in thousands)
|
632,918
|
670,013
|
672,429
|
675,331
|
675,331
|
-
|
Reference price
2 |
23.73
|
10.84
|
8.443
|
3.380
|
3.380
|
3.380
|
Announcement Date
|
3/29/21
|
3/31/22
|
3/31/23
|
3/28/24
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net sales
1 |
38.66
|
136.5
|
250.8
|
441.1
|
681.6
|
937.8
|
EBITDA
1 |
-384.2
|
-215.8
|
-517.2
|
-375.8
|
-177.9
|
-59.03
|
EBIT
1 |
-403.7
|
-243.3
|
-562
|
-434.7
|
-278
|
-102.7
|
Operating Margin
|
-1,044.41%
|
-178.22%
|
-224.05%
|
-98.54%
|
-40.79%
|
-10.96%
|
Earnings before Tax (EBT)
1 |
-
|
-574.2
|
-398.2
|
-391.5
|
-246.1
|
-80.89
|
Net income
1 |
-
|
-574.2
|
-407.8
|
-392.5
|
-246.1
|
-80.89
|
Net margin
|
-
|
-420.57%
|
-162.58%
|
-88.98%
|
-36.1%
|
-8.63%
|
EPS
2 |
-
|
-0.8600
|
-0.6100
|
-0.5800
|
-0.3600
|
-0.1200
|
Free Cash Flow
1 |
-206.4
|
-506.1
|
-578.5
|
-512
|
-465
|
-282
|
FCF margin
|
-533.84%
|
-370.68%
|
-230.65%
|
-110.26%
|
-68.22%
|
-30.07%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/29/21
|
3/31/22
|
3/31/23
|
3/28/24
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
2,449
|
2,288
|
1,538
|
887
|
480
|
184
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-206
|
-506
|
-579
|
-512
|
-465
|
-282
|
ROE (net income / shareholders' equity)
|
-34.9%
|
-8.9%
|
-18.2%
|
-12.9%
|
-10.6%
|
-5.98%
|
ROA (Net income/ Total Assets)
|
-20.9%
|
-
|
-15.9%
|
-9.11%
|
-
|
-
|
Assets
1 |
-
|
-
|
2,568
|
3,874
|
-
|
-
|
Book Value Per Share
2 |
4.450
|
4.530
|
3.920
|
3.450
|
2.950
|
2.830
|
Cash Flow per Share
2 |
-
|
-
|
-0.5600
|
-0.4900
|
-
|
-
|
Capex
1 |
25.3
|
69.7
|
202
|
265
|
296
|
318
|
Capex / Sales
|
65.33%
|
51.08%
|
80.67%
|
57.12%
|
43.43%
|
33.91%
|
Announcement Date
|
3/29/21
|
3/31/22
|
3/31/23
|
3/28/24
|
-
|
-
|
Last Close Price
3.38
CNY Average target price
11.1
CNY Spread / Average Target +228.38% Consensus |
1st Jan change
|
Capi.
|
---|
| -50.47% | 317M | | +9.86% | 126B | | -5.47% | 11.33B | | +4.83% | 9.27B | | +35.76% | 5.5B | | -24.78% | 4.61B | | +8.68% | 3.45B | | -9.69% | 2.81B | | -10.99% | 2.09B | | -10.20% | 2.08B |
Medical Devices & Implants
|